Cargando…
Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578493/ https://www.ncbi.nlm.nih.gov/pubmed/33145076 http://dx.doi.org/10.21037/jtd-20-1817 |
_version_ | 1783598378405330944 |
---|---|
author | Lemmon, Christopher Pennell, Nathan A. |
author_facet | Lemmon, Christopher Pennell, Nathan A. |
author_sort | Lemmon, Christopher |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-7578493 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-75784932020-11-02 Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough? Lemmon, Christopher Pennell, Nathan A. J Thorac Dis Editorial Commentary AME Publishing Company 2020-09 /pmc/articles/PMC7578493/ /pubmed/33145076 http://dx.doi.org/10.21037/jtd-20-1817 Text en 2020 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Editorial Commentary Lemmon, Christopher Pennell, Nathan A. Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough? |
title | Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough? |
title_full | Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough? |
title_fullStr | Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough? |
title_full_unstemmed | Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough? |
title_short | Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough? |
title_sort | use of adjuvant egfr tyrosine kinase inhibitors in early stage egfr-mutant non-small cell lung cancer: is the evidence strong enough? |
topic | Editorial Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578493/ https://www.ncbi.nlm.nih.gov/pubmed/33145076 http://dx.doi.org/10.21037/jtd-20-1817 |
work_keys_str_mv | AT lemmonchristopher useofadjuvantegfrtyrosinekinaseinhibitorsinearlystageegfrmutantnonsmallcelllungcanceristheevidencestrongenough AT pennellnathana useofadjuvantegfrtyrosinekinaseinhibitorsinearlystageegfrmutantnonsmallcelllungcanceristheevidencestrongenough |